The Story of GLP-1
A Historical Journey in the Treatment of Diabetes and Obesity
- Publisher's listprice EUR 162.99
-
67 600 Ft (64 381 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 6 760 Ft off)
- Discounted price 60 840 Ft (57 943 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
67 600 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Elsevier Science
- Date of Publication 3 March 2026
- ISBN 9780443332876
- Binding Hardback
- No. of pages188 pages
- Size 229x152 mm
- Weight 450 g
- Language English 692
Categories
Long description:
The Story of GLP-1: A Historical Journey in the Treatment of Diabetes and Obesity offers a compelling narrative about the discovery and development of the hormone GLP-1, which has revolutionized modern approaches to diabetes and obesity. Award-winning scientist Professor Jens Juul Holst, alongside co-authors Professor Sten Madsbad, Professor Jens Meldgaard Bruun, and Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen, trace the scientific breakthroughs and clinical advances that have made GLP-1 therapies, such as Ozempic and Wegovy, essential tools for improving blood sugar control and promoting meaningful, lasting weight loss in patients worldwide.
The book explores the rising global prevalence of obesity and diabetes, emphasizing the urgent need for innovative solutions. It critically examines traditional treatments, noting their limitations in sustaining weight loss or reducing complications. The narrative details the paradigm shift brought by GLP-1 medications, including liraglutide and semaglutide, which offer improved cardiovascular outcomes and significant health benefits. The authors also address ongoing challenges of accessibility and affordability, prompting important societal discussions about equitable distribution and funding for these lifechanging therapies.
Table of Contents:
1. The Incretin Effect
2. GLP-1 and the Gastrointestinal Tract
3. GLP-1 and Food Intake
4. GLP-1 and Diabetes
5. GLP-1 and Diabetes Treatment
6. GLP-1 receptor Agonists (GLP-1 RA)
7. Weight Loss and Diabetes Treatment
8. GLP-1 and Weight Loss
9. GLP-1 and society
10. The Discovery and Development of Human GLP-1
